Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients (BEATLE)

  • days left to enroll
  • participants needed
  • sponsor
    Hospital Universitari de Bellvitge
Updated on 24 February 2022
antibiotic therapy
stem cell transplantation
neutrophil count


This study evaluates the administration of beta-lactam antibiotics in extended infusion in hematological patients with febrile neutropenia after 5 days of treatment. The beta-lactam antibiotics analyzed are the following: piperacillin-tazobactam, cefepime and meropenem. Half of patients will receive the antibiotic in intermittent infusion, while the other half will receive it in extended infusion.


Febrile neutropenia (FN) is a very frequent complication in patients with hematological malignancies. It is associated with an important morbidity and mortality. Nowadays the use of betalactam antibiotics (BLA) in extended or continuous infusion (EI, CI) instead of intermittent infusion (II), has demonstrated a therapeutic success and lower mortality rate in critically ill intensive care patients. Neutropenic patients are a particular population since FN is assoicated with pathophysiological variations that compromise pharmacokinetic parameters of BLA, and may therefore, diminish their clinical efficacy. Information regarding the usefulness of BLA in EI in neutropenic hematologic patients is scarce.

The objective of this randomized clinical trial is to demonstrate the clinical superiority of the administration of BLA in EI compared to II in patients with FN.

Condition Febrile Neutropenia
Treatment Piperacillin-Tazobactam 4 g-0.5 g, Cefepime 2000 mg, Meropenem 1000 mg
Clinical Study IdentifierNCT04233996
SponsorHospital Universitari de Bellvitge
Last Modified on24 February 2022


Yes No Not Sure

Inclusion Criteria

Adult patients (age 18 years) of both sexes
Patients admitted in Hematological wards
With any of the following diagnoses
Acute leukemia receiving chemotherapy
Autologous or allogeneic hematopoietic stem cell transplant recipients
With an episode of febrile neutropenia: 38.0C and <500 neutrophils/mm3 or <1000 with a predicted decrease within 24-48 hours
Patient requiring treatment with a beta-lactam antibiotic: cefepime, piperacillin /tazobactam or meropenem, in monotherapy or in combination with another antibiotic
Written informed consent has been obtained from the patient or their legal representative grants

Exclusion Criteria

Allergy to study drugs
Patient receiving systemic antibiotic treatment (except for prophylaxis) at the time of onset of febrile neutropenia
Absence of fever
Patients with epilepsy
Severe renal impairment (defined as creatinine clearance <30 mL / min)
Previously enrolled patients in whom the time between the inclusion and the current episode is less than 5 weeks
Previously enrolled patients without current resolution of the first episode
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note